Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a biopharmaceutical company focused on abuse-deterrent drug formulation technology that reached the public markets through a SPAC merger with Leisure Acquisition Corp. in 2021. The company filed a Form 10-Q with the U.S. Securities and Exchange Commission on August 7, 2019, providing quarterly financial disclosures during its pre-merger development phase. Operating in the healthcare and pharmaceutical sector, Ensysce has advanced a proprietary pipeline of drug formulations designed to reduce the misuse potential of prescription medications. The August 2019 filing is one of several periodic reports tracked on SpacDesk as part of its full SPAC deal and post-merger filing history. Sign up at SpacDesk for complete filing data, deal timelines, and sponsor records on ENSC and the broader SPAC universe.